R&D

acquisition merger arrows
Biotech

AbbVie ends development of IL-1 asset in ulcerative colitis

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis after a phase 2 study revealed insufficient efficacy results.
Gabrielle Masson Jul 31, 2025 12:32pm
Open farm gate leading into agricultural landscape

Lilly links up with Gate in $856M biobucks deal

Jul 24, 2025 2:32pm
Expensive laboratory tests

TCG Labs Soleil raises $400M for single-asset biotechs

Jul 24, 2025 7:00am
team layoffs workforce

GSK plans 'very limited' job cuts for global R&D team

Jul 15, 2025 4:15pm
Group of scientist or doctors and nurses wearing blue protective gloves putting their hands together

Revolution taps Iambic's AI models in $25M discovery deal

Jul 9, 2025 11:19am
arrows on dice organized forward

CSL consolidates R&D team in shift toward external partners

Jul 7, 2025 12:44pm